The strong antitumor activity observed in vivo and in vitro suggests that zanidatamab will show activity in the clinical setting, and perhaps even with greater efficacy than the current anti-HER2 therapies and in indications outside of breast and gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.